{"id":820741,"date":"2025-03-03T13:18:48","date_gmt":"2025-03-03T18:18:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/"},"modified":"2025-03-03T13:18:48","modified_gmt":"2025-03-03T18:18:48","slug":"revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/","title":{"rendered":"Revance Therapeutics, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact The Gross Law Firm for More Information \u2013 RVNC"},"content":{"rendered":"
\n

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).<\/strong><\/p>\n

Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n

CONTACT US HERE:<\/p>\n

\n https:\/\/securitiesclasslaw.com\/securities\/revance-therapeutics-inc-loss-submission-form-2\/?id=132988&from=3<\/a>\n <\/p>\n

\n CLASS PERIOD: <\/strong>February 29, 2024 to December 6, 2024<\/p>\n

\n ALLEGATIONS: <\/strong>The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (i) Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance \u201cthe exclusive right to import, market, promote, sell and distribute Teoxane\u2019s line of dermal fillers; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; (iii) all the foregoing increased the risk that the tender offer would be delayed and\/or amended; and (iv) as a result, the Company\u2019s public statements were materially false and misleading at all relevant times.<\/p>\n

\n DEADLINE: March 4, 2025<\/strong> Shareholders should not delay in registering for this class action. Register your information here: https:\/\/securitiesclasslaw.com\/securities\/revance-therapeutics-inc-loss-submission-form-2\/?id=132988&from=3<\/a>\u00a0<\/p>\n

\n NEXT STEPS FOR SHAREHOLDERS: <\/strong>Once you register as a shareholder who purchased shares of RVNC during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 4, 2025. There is no cost or obligation to you to participate in this case.<\/p>\n

\n WHY GROSS LAW FIRM? <\/strong>The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and\/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n

\n CONTACT:<\/strong>
\n
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com<\/a>\u00a0
Phone: (646) 453-8903<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/revance-therapeutics-inc-loss-submission-form-2\/?id=132988&from=3 CLASS PERIOD: February 29, 2024 to December 6, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (i) Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance \u201cthe exclusive right to import, market, promote, sell and distribute Teoxane\u2019s line of … <\/p>\n

Continue reading “Revance Therapeutics, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact The Gross Law Firm for More Information \u2013 RVNC”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-820741","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRevance Therapeutics, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact The Gross Law Firm for More Information \u2013 RVNC - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revance Therapeutics, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact The Gross Law Firm for More Information \u2013 RVNC - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/revance-therapeutics-inc-loss-submission-form-2\/?id=132988&from=3 CLASS PERIOD: February 29, 2024 to December 6, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (i) Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance \u201cthe exclusive right to import, market, promote, sell and distribute Teoxane\u2019s line of … Continue reading "Revance Therapeutics, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact The Gross Law Firm for More Information \u2013 RVNC"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-03T18:18:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Njk0MSM2Nzg1MDI0IzIyNTg5MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Revance Therapeutics, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact The Gross Law Firm for More Information \u2013 RVNC\",\"datePublished\":\"2025-03-03T18:18:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\\\/\"},\"wordCount\":411,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Njk0MSM2Nzg1MDI0IzIyNTg5MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\\\/\",\"name\":\"Revance Therapeutics, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact The Gross Law Firm for More Information \u2013 RVNC - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Njk0MSM2Nzg1MDI0IzIyNTg5MTc=\",\"datePublished\":\"2025-03-03T18:18:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Njk0MSM2Nzg1MDI0IzIyNTg5MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Njk0MSM2Nzg1MDI0IzIyNTg5MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revance Therapeutics, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact The Gross Law Firm for More Information \u2013 RVNC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revance Therapeutics, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact The Gross Law Firm for More Information \u2013 RVNC - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/","og_locale":"en_US","og_type":"article","og_title":"Revance Therapeutics, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact The Gross Law Firm for More Information \u2013 RVNC - Market Newsdesk","og_description":"NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/revance-therapeutics-inc-loss-submission-form-2\/?id=132988&from=3 CLASS PERIOD: February 29, 2024 to December 6, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (i) Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance \u201cthe exclusive right to import, market, promote, sell and distribute Teoxane\u2019s line of … Continue reading \"Revance Therapeutics, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact The Gross Law Firm for More Information \u2013 RVNC\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-03T18:18:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Njk0MSM2Nzg1MDI0IzIyNTg5MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Revance Therapeutics, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact The Gross Law Firm for More Information \u2013 RVNC","datePublished":"2025-03-03T18:18:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/"},"wordCount":411,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Njk0MSM2Nzg1MDI0IzIyNTg5MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/","name":"Revance Therapeutics, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact The Gross Law Firm for More Information \u2013 RVNC - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Njk0MSM2Nzg1MDI0IzIyNTg5MTc=","datePublished":"2025-03-03T18:18:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Njk0MSM2Nzg1MDI0IzIyNTg5MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Njk0MSM2Nzg1MDI0IzIyNTg5MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revance-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more-information-rvnc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Revance Therapeutics, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact The Gross Law Firm for More Information \u2013 RVNC"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/820741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=820741"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/820741\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=820741"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=820741"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=820741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}